The Inherited Neurodegenerative Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Inherited Neurodegenerative Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Inherited Neurodegenerative Diseases. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Inherited Neurodegenerative Diseases and features dormant and discontinued products.

GlobalData tracks 35 drugs in development for Inherited Neurodegenerative Diseases by 31 companies/universities/institutes. The top development phase for Inherited Neurodegenerative Diseases is preclinical with 24 drugs in that stage. The Inherited Neurodegenerative Diseases pipeline has 30 drugs in development by companies and five by universities/ institutes. Some of the companies in the Inherited Neurodegenerative Diseases pipeline products market are: Virtus Therapeutics, Polaryx Therapeutics and Orphi Therapeutics.

The key targets in the Inherited Neurodegenerative Diseases pipeline products market include Beta-Hexosaminidase Subunit Alpha (Beta-N-Acetylhexosaminidase Subunit Alpha or N-Acetyl-Beta-Glucosaminidase Subunit Alpha or HEXA or EC 3.2.1.52), Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80), and Copper.

The key mechanisms of action in the Inherited Neurodegenerative Diseases pipeline product include Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Inhibitor with three drugs in Phase III. The Inherited Neurodegenerative Diseases pipeline products include seven routes of administration with the top ROA being Oral and eight key molecule types in the Inherited Neurodegenerative Diseases pipeline products market including Small Molecule, and Gene Therapy.

Inherited Neurodegenerative Diseases overview

Inherited neurodegenerative diseases are a group of disorders that affect the structure and function of neurons, leading to progressive loss of cognitive and motor abilities. Some of these diseases are caused by mutations in single genes, such as Huntington’s disease, while others are influenced by multiple genetic and environmental factors, such as Alzheimer’s disease and Parkinson’s disease. The mechanisms of neuronal death in these diseases are not fully understood, but they often involve abnormal protein aggregation, oxidative stress, inflammation, and mitochondrial dysfunction. Inherited neurodegenerative diseases have no cure, but research is ongoing to find ways to prevent, slow down, or reverse the neuronal damage.

For a complete picture of Inherited Neurodegenerative Diseases’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.